About US
Contact us
-
Alexion gets FDA warning but doesn't expect Soliris disruptionAlexion is facing a tough situation for a one-hit wonder. It has been issued an FDA warning letter for its manufacturing plant where it makes its only approved drug--the rare-disease, and very pricey2013/4/1
-
Drugmakers need to think local in emerging markets, execs sayDrugmakers know by now that emerging markets aren't a quick fix. Though fast-developing countries such as China and India offer the promise of fast growth in drug sales, it's more difficult to tap th2013/4/1
-
Roche's Japanese arm gets green light for new arthritis drug trialChugai has been given the go-ahead to start clinical trials of its new arthritis treatment in Japan. The Japanese subsidiary of Roche has confirmed that regulators in the country have given the offic2013/3/29
-
Biopharmaceutical clinical trials boost Texas economyOver the last 13 years, biopharmaceutical companies in the US have conducted more than 8,200 clinical trials of new medicines in Texas.That is according to the Pharmaceutical Research and Manufacture2013/3/29
-
Novo, Sanofi duke it out in diabetes marketIf you've been following Novo Nordisk's ($NVO) new diabetes drugTresiba, you know that it will take aim at Sanofi's ($SNY) big gorilla of a basal insulin drug,Lantus. The stakes are huge for Sanofi,2013/3/28
-
ASCO aims Big Data at cancer treatmentTheAmerican Society of Clinical Oncologyis developing a database ofcancerpatients that could change the way doctors select treatments. With medical records on millions of people, the Big Data project2013/3/28
-
Despite sales slide, Bristol-Myers CEO nabs 15% raise to $17.2MBristol-Myers Squibb CEOLamberto Andreottigot a 15% raise last year. And that's on top of a 26% increase the year before. Andreotti's 2012 compensation package amounted to $17.2 million, up from $11.2013/3/27
-
InteRNA Technologies Secures Additional Equity Financing to Progress Lead Program for Melanoma TreatmentInteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing of an equity financing round. New investors2013/3/27
-
Novartis, Early copies of Sanofi's Aubagio could roil European MS marketTheEuropean Medicines Agency's drug-review committee has recommended approval for Sanofi's ($SNY) newmultiple sclerosistreatmentAubagio. But the EMA says it doesn't deserve "new active substance" stat2013/3/26
-
CoCo Therapeutics Ltd Announces the Appointment of its Clinical and Scientific Advisory GroupCoCo Therapeutics Ltd, a newly formed UK Biotechnology Company today announced the appointment to its Clinical and Scientific Advisory Group of Clive Ballard, Jonathan Corcoran, Roy Lobb, Andrew Wood2013/3/26